Dr. Greg Riely from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.

Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.

Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

[powerpress]

Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]